Trial
REGISTER
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

Trial

› Forums › General Melanoma Community › Trial

  • Post
    • December 30, 2016 at 5:19 pm
    Shaneswife
    Participant
      Is anyone here in this trial and can provide some insights?

      Summary
      Eligibility & Details
      A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma

      NCT #: NCT02752074
      Lead Sponsor: Incyte Corporation
      Disease Site Group: Skin
      Disease Site Location: Melanoma
      Trial Phase: 5
      Disease Stage: Advanced Cancer
      Treatment Line: First Line
      Interventions:
      Drug : pembrolizumab + epacadostat
      Drug : pembrolizumab + placebo

      Thanks in advance

      Janis

    Viewing 8 reply threads
    • Replies
    Viewing 8 reply threads

    Tagged: 

    • You must be logged in to reply to this topic.
    About the MRF Patient Forum

    The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

    The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

    Popular Topics